Lilly divests China rights to legacy antibiotics to Eddingpharm

Lilly sold Chinese rights to Vancocin vancomycin and Ceclor cefaclor, as well as a

Read the full 140 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE